Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06437574

Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer

Lowering Cholesterol in Prostate Cancer to Target Rapamycin-Insensitive Companion Of MTOR (TORC2) in T-Cell Surface Glycoprotein CD8 Alpha Chain (CD8+) Lymphocytes

Sponsor: Cedars-Sinai Medical Center

Conditions Prostate Cancer

Interventions Ezetimibe Vytorin

Updated 7 times since 2024 Last updated: Mar 9, 2026 Started: Jul 16, 2024 Primary completion: Feb 29, 2028 Completion: May 31, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Prostate Cancer and is currently actively recruiting participants. Cedars-Sinai Medical Center leads this study, which shows 7 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE2
Mar 2025 — Mar 2026 [monthly]

Recruiting PHASE2
Nov 2024 — Mar 2025 [monthly]

Recruiting PHASE2
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 2 earlier versions

Jul 2024 — Aug 2024 [monthly]

Not Yet Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cedars-Sinai Medical Center

Data source: Cedars-Sinai Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Los Angeles, United States